Top 15 Oncology Medicines by Q2 2024 Sales

Oncology remains the largest segment of the BioPharma industry, hosting many of the industry’s top-selling medicines. Several key drugs are facing LOEs soon. Here’s a closer look behind key catalysts driving development and growth:

August 29, 2024

Roche: 10 Year Sales Evolution

Roche has achieved steady growth in the last several years, yet underneath, it has undergone significant change. Here are a few highlights about how it has evolved over the last decade:

August 21, 2024

Top 10 Medicines by Q2 2024 Sales

All major public BioPharma companies have reported Q2 results. Here's a look behind the world's 10 top-selling medicines:

August 21, 2024

IRA's First 10: How Much Revenue is at Stake?

In the initial 10 medicines under the IRA, there is a huge variance in terms of how much each company's revenue is dependent on that medicine. Here's a fresh take on the relative impact:

August 21, 2024

Alzheimer's Disease Landscape

Last month, the EMA rejected Biogen's Leqembi, despite the FDA’s previous approval, citing major safety risks that involve ARIA (brain bleeding and/or swelling). Here’s a closer look at Leqembi and other promising Alzheimer’s treatments:

August 15, 2024

Lilly and Novo: How do GLP-1 Sales Compare? (Q2 '24)

Last week, both Eli Lilly and Company and Novo Nordisk reported quarterly results, where the focus continued to be on the companies' GLP-1 medicines. Here are some notable updates on manufacturing expansion, intl. sales, and access.

August 14, 2024

AstraZeneca's Top 10 Medicines by Sales in Q2 '24

AstraZeneca reported quarterly earnings a few days back, demonstrating continued strong growth, especially in oncology. Here’s a more detailed look at some of the highlights:

August 12, 2024

Sanofi Revenue by Category - Q2 '24 Earnings Recap

Sanofi announced Q2 results recently, including continued strong growth from Dupixent, along with several new launches and pipeline updates. Here's a deeper dive:

August 12, 2024

BMS Top 10 Medicines by Sales in Q2 '24

Bristol Myers Squibb (BMS) reported its second-quarter earnings last week, showcasing strong growth in its newer medicines portfolio and better-than-expected results for its mature medicines. Here is a closer look at BMS's performance for the quarter:

August 02, 2024

Top 10 BioPharma Companies by Revenue (2003 to 2023)

Over the past 20 years, the top 10 Biopharma companies have almost doubled revenue. Yet, there has been considerable variance among companies. Here's a closer look behind some of the most notable changes.

August 01, 2024